Search Results
SPARSENTAN In IgA Nephropathy: An Update On The Clinical Trials
Clinical Trial: Sparsentan for Treatment of IgA Nephropathy
An update on clinical trials and new treatments in IgA nephropathy (2023)
Explaining Sparsentan’s Full FDA Approval and Other IgA Nephropathy Therapeutic Developments
Targeting Glomerular Injury with Sparsentan to Preserve Kidney Function in Patients with IgA
Accelerated Approval for IgA Nephropathy Treatment
Clinical Trials in Nephrology: IgA Nephropathy
Emerging Therapeutics: IgA Nephropathy
Nephrology Update: Highlights from ASN Kidney Week 2023
Clinical Trials; Why are they topical?
IgA Nephropathy: Developing a Non-Immunosuppressive Therapy
NEW TREATMENT for KIDNEY DISEASE - Hope for IgA Nephropathy? #nowapproved
